Prostate Gland: MR Imaging Appearance after Vascular Targeted Photodynamic Therapy with Palladium-Bacteriopheophorbide

Abstract

Contrast-enhanced MR imaging depicts irregular margins of intraprostatic treatment effect. This finding suggests varied tissue sensitivities to VTP with palladium-bacteriopheophorbide.

Contrast-enhanced ultrasonography for real-time monitoring of interstitial laser thermal therapy in the focal treatment of prostate cancer

“…16,17 Based on the example described here, the coagulated lesion measured by intraoperative CEUS appears to correspond well with the lesion measured using Gd-enhanced MRI at 7 days, suggesting that intraoperative CEUS provides a promising measure of the actual treatment effect. Further detailed studies are planned with more patients to confirm this correspondence, and where possible, to compare treatment effect measured with CEUS to whole-mount pathology samples of patients who subsequently undergo radical prostatectomy.…”

“…16 Magnetic resonance imaging scans were imported and registered to similar anatomical features in Variseed. The edge of the prostate was traced on the T 2 -weighted series and intraprostatic devascularized areas were identified by tracing dark areas on the Gd-enhanced T 1 -weighted series.…”

Dynamic contrast enhanced MRI as a predictor of vascular-targeted photodynamic focal ablation therapy outcome in prostate cancer post failed external beam radiation therapy

“…11 The current study involves a retrospective analysis performed on a subgroup from this cohort. Approval was obtained from the ethics review board and all patients signed informed consent forms.…”

“…Regions showing <10% enhancement on the last DCE phase were also considered necrotic. 11 The prostate volume was derived by contouring on axial T2-weighted images; a region-of-interest was drawn around the necrotic margin to calculate volume and derive the percentage volume of necrosis ( Table 1). …”

“…Palladium-bacteriopheophorbide (WST09, Steba-Biotech N.V., The Hague, Netherlands, and Negma, Toussus-leNoble, France) is a PDT agent which has demonstrated promising results in Phase I and II trials for prostate cancer. [11][12][13][14] The agent induces vascular occlusion, with subsequent ischemic necrosis of the targeted area. 15,16 It is therefore intuitive that contrast-enhanced magnetic resonance imaging (MRI) could be used to monitor treatment response.…”